Management of renal osteodystrophy in children

Turkish Journal of Pediatrics

Volumn 47, Issue SUPPL., 2005, Pages 13-18

  Tasic, Velibor ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Macedonia)

Author keywords

Adynamic bone disease; Children; Hyperparathyroidism; Management; Renal osteodystrophy

Indexed keywords

ALKALINE PHOSPHATASE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CALCIUM SENSING RECEPTOR; CINACALCET; CORTICOSTEROID; FERRIC CITRATE; GROWTH HORMONE; LANTHANUM CARBONATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D DERIVATIVE;

ACIDOSIS; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE BIOPSY; BONE PAIN; CALCIUM BLOOD LEVEL; CHILD; CHILD NUTRITION; CHILDHOOD DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; FRACTURE; GROWTH RETARDATION; HEMODIALYSIS; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY AND SPECIFICITY;

BONE AND BONES; CHILD; GROWTH HORMONE; HUMANS; HYDROXYLATION; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; PARATHYROIDECTOMY; PHOSPHATES; PHOSPHORUS; RECEPTORS, CALCIUM-SENSING; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 17844396634     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Sanchez CP. Prevention and treatment of renal osteodystrophy in children with chronic renal insufficiency and end-stage renal disease. Semin Nephrol 2001; 21: 441-450.
2. Sanchez CP. Secondary hyperparathyroidism in children with chronic renal failure. Pathogenesis and treatment. Pediatr Drugs 2003; 5: 763-776.
3. Slatopolsky E, Gonzalez E, Martin K. Pathogenesis and treatment of renal osteodystrophy. Blood Purif 2003; 21: 318-326.
4. Avbersek-Luznik I, Malesic I, Rus I, Marc I. Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med 2002; 40: 1019-1023.
5. Yalcinkaya F, Ince E, Tumer N, Ensari A, Ozkaya N. Spectrum of renal osteodystrophy in children on continuous ambulatory peritoneal dialysis. Pediatr Int 2000; 42: 53-57.
6. Ziolkowska H, Paniczyk-Tomaszewska M, Debinski A, Polowiec Z, Sawicki A, Sieniawska M. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr 2000; 89: 666-671.
7. Mathias R, Salusky I, Harman W, et al. Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital. J Am Soc Nephrol 1993; 3: 1938-1946.
8. Gal-Moscovici A, Popovtzer MM. Parathyroid hormone-independent osteoclastic resorptive bone disease: a new variant of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 2002; 17: 620-624.
9. Salusky I, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG. Biochemical markers of renal ostedystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994; 45: 253-258.
10. Waller S, Ledermann S, Trompeter R, van't Hoff W, Ridout D, Rees L. Catch-up growth with normal parathyroid hormone levels in chronic renal failure. Pediatr Nephrol 2003; 18: 1236-1241.
11. Waller S, Reynolds A, Ridout D, Cantor T, Gao P, Rees L. Parathyroid hormone and its fragments in children with chronic renal failure. Pediatr Nephrol 2003, 18: 1242-1248.
12. Malluche HH, Mawad H, Trueba D, Monier-Faugere MC. Parathyroid hormone assays-evolution and revolutions in the care of dialysis patients. Clin Nephrol 2003; 59: 313-318.
13. Salusky IB, Juppner H. New PTH assays and renal osteodystrophy. Pediatr Nephrol 2004; 19: 709-713.
14. Milliner DS, Zinsmeister AR, Lieberman E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990; 38: 931-936.
15. Katsumata K, Kusano K, Hirata M, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003; 64: 441-450.
16. Mahdavi H, Kuizon BD, Gales B, Wang H-J, Elashoff RM, Salusky IB. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol 2003; 18: 1260-1264.
17. Ferrara E, Lemire J, Reznik VM, Grimm PC. Dietary phosphorus reduction by pretreatment of human breast milk by sevelamer. Pediatr Nephrol 2004, 19: 775-779.
18. Nolan CR, Qunibi WY. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens 2003; 12: 373-379.
19. D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; 85: S73-78.
20. Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant 2002; 17: 265-270.
21. Ardissino G, Schmitt CP, Testa S, Claris-Appiani A, Mehls O. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure. Pediatr Nephrol 2000; 14: 664-668.
22. Tsuruoka S, Wakaumi M, Sugimoto K, Saito T, Fujimura A. Chronotherapy of high-dose active vitamin D3 in haemodialysis patients with secondary hyperparathyroidism: a repeated dosing study. Br J Clin Pharmacol 2003; 5: 531-537.
23. Shaefer K, Umlauf E, Herrath DV. Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. Am J Kidney Dis 1992; 19: 460-464.
24. Moe SM, Kraus MA, Gassensmith CM, Fineberg NS, Gannon FH, Peacock M. Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. Nephrol Dial Transplant 1998; 13: 1234-1241.
25. Sanchez CP. Chronotherapy of high-dose active vitamin D3: is evening dosing preferable. Pediatr Nephrol 2004; 19: 722-723.
26. Cunningham J. New vitamin D analogues for osteodystrophy in chronic kidney disease. Pediatr Nephrol 2004; 19: 705-708.
27. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490.
28. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
29. Kommala D, Benador N, Goldstein S, et al. Paricalcitol (Zemplar) injections for the treatment of secondary hyperparathyroidism in pediatric hemodialysis patients. Proceedings of the American Society of Nephrology, San Diego, 2003.
30. Llach F, Qui EA, Ross EA, et al. Paricalcitol (Zemplar) capsule controls secondary hyperparathyroidism in chronic hemodialysis patients. Proceedings of the American Society of Nephrology, San Diego, 2003.
31. Olgaard K, Lewin E. Prevention of uremic bone disease using calcimimetic compounds. Annu Rev Med 2001; 52: 203-220.
32. Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials. Pediatr Nephrol 2003; 18: 1206-1210.
33. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
34. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63: 248-254.
35. Urena Torres P. Clinical experience with cinacalcet HCl. Nephrol Dial Transplant 2004; 19 (Suppl): V27-V33.
36. Watkins SL. Does renal osteodystrophy develop and/or progress during the course of rhGH treatment? Br J Clin Pract Suppl 1996; 85: 59-60.
37. Hokken-Koelega A, Mulder P, De Jong R, Lilien M, Donckerwolcke R, Groothof J. Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency. Pediatr Nephrol 2000; 14: 701-706.